see below
Begin forwarded message:
From: Victoria Manning vmanning@hsc.mb.ca Date: December 11, 2025 at 11:08:44 AM CST To: Ethan Bohn ebohn4@hsc.mb.ca, "Marshall Tenenbein, Dr." mtenenbein2@hsc.mb.ca Subject: FW: Fragmin
Hi Ethan and Marshall,
Could you forward to the Anesthesia Group that all of the thoracic surgeons will now be using Fragmin instead of Heparin. It is stocked in the med room and in the drawers in Th. 4 & 5.
Thanks !
Vickie
From: Karen Sagness KSagness@hsc.mb.ca Sent: Thursday, December 11, 2025 8:58 AM To: HSC Adult OR - Perioperative Aides HSCAdultOR-PerioperativeAides@exchange.hsc.mb.ca Cc: Victoria Manning vmanning@hsc.mb.ca Subject: Fragmin
Good morning!
Just to let you all know that thoracic surgery would like 3 pre-filled Fragmin syringes to be stocked in both Th. 4 and 5 effective immediately. They will still need heparin to remain in both theatres as well. I will update the drug list and have it relaminateed to hang at the side of all carts.
Please see me if you have questions. Have a good Thursday!
Karen
Karen Sagness RN CPN© RNFA Manager of Health Services, Adult Operating Room Surgery Program | HSC Winnipeg Shared Health Location: JJ272 Mail: JJ272 - 820 Sherbrook St, Winnipeg MB R3A 1R9 Email: ksagness@hsc.mb.camailto:ksagness@hsc.mb.ca Mobile: 431-323-3418 Fax: 204-787-3095 www.hsc.mb.cahttp://www.hsc.mb.ca/ | www.sharedhealthmb.cahttp://www.sharedhealthmb.ca/
Disclaimer : This email (including any attachments or enclosed documents) is intended for the addressee(s) only and may contain privileged, proprietary or confidential information. Any unauthorized use, disclosure, distribution, copying or dissemination is strictly prohibited. If you receive this email in error, please notify the sender immediately, return the original (if applicable) and delete the email. Avis : Le présent courriel (y compris toute pièce jointe) est destiné à la personne ou aux personnes à qui il est adressé, et peut contenir des renseignements confidentiels, privés ou protégés par un privilège juridique. Toute utilisation, divulgation, distribution, copie ou diffusion non autorisée est strictement défendue. Si vous avez reçu le présent courriel par erreur, veuillez en informer immédiatement l’expéditeur, retourner l’original (le cas échéant) et supprimer ce courriel.
participants (1)
-
Marshall Tenenbein, Dr.